Table 2A
Open in new tab

Association between ApoA1 levels and adverse outcomes. Overall cohort

OutcomeModel0.42–1.22 g/L (95% CI)1.23–1.32 g/L (95% CI)1.33–1.39 g/L (95% CI)1.40–1.45 g/L (95% CI)1.46–1.52 g/L (95% CI)1.53–1.59 g/L (95% CI)1.60–1.66 g/L (95% CI)1.67–1.75 g/L (reference)1.76–1.91 g/L (95% CI)1.91–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.65 (1.56–1.75); P < 0.00011.32 (1.25–1.40); P < 0.00011.17 (1.10–1.24); P < 0.00011.08 (1.02–1.15); P = 0.00741.03 (0.97–1.10); P = 0.28871.07 (1.01–1.13); P = 0.03411.02 (0.96–1.08); P = 0.60251.001.03 (0.97–1.10); P = 0.30851.09 (1.03–1.15); P = 0.0053
Adjusteda1.31 (1.24–1.39); P < 0.00011.13 (1.06–1.20); P < 0.00011.03 (0.97–1.09); P = 0.35631.00 (0.94–1.06); P = 0.90070.97 (0.91–1.03); P = 0.26421.02 (0.96–1.08); P = 0.49890.99 (0.93–1.05); P = 0.75451.001.06 (1.00–1.13); P = 0.05331.14 (1.07–1.21); P < 0.0001
PGS Adjustedb1.29 (1.22–1.37); P < 0.00011.12 (1.05–1.18); P = 0.00041.02 (0.96–1.08); P = 0.54950.99 (0.93–1.05); P = 0.73160.96 (0.91–1.03); P = 0.23771.02 (0.96–1.08); P = 0.61020.99 (0.93–1.05); P = 0.69581.001.07 (1.01–1.14); P = 0.0321.15 (1.08–1.22); P < 0.0001
CV mortalityUnadjusted2.08 (1.87–2.31); P < 0.00011.52 (1.36–1.69); P < 0.00011.32 (1.18–1.47); P < 0.00011.24 (1.10–1.39) P = 0.00021.11 (0.99–1.25) P = 0.07881.22 (1.08–1.36); P = 0.00081.05 (0.94–1.18); P = 0.39751.001.11 (0.99–1.25); P = 0.08111.09 (0.96–1.23); P = 0.1757
Adjusteda1.35 (1.20–1.51); P < 0.00011.12 (1.00–1.26); P = 0.04561.03 (0.91–1.15); P = 0.66221.03 (0.92–1.16); P = 0.59460.95 (0.85–1.07); P = 0.41791.10 (0.98–1.23); P = 0.11430.99 (0.88–1.12); P = 0.86761.001.18 (1.04–1.33); P = 0.00761.21 (1.07–1.37); P = 0.0022
PGS Adjustedb1.30 (1.16–1.46); P < 0.00011.09 (0.97–1.23); P = 0.13961.00 (0.89–1.13); P = 0.96171.01 (0.90–1.14); P = 0.820.94 (0.83–1.06); P = 0.29621.08 (0.96–1.22); P = 0.18680.99 (0.88–1.11); P = 0.84071.001.19 (1.05–1.34); P = 0.00561.23 (1.09–1.39); P = 0.0011
OutcomeModel0.42–1.22 g/L (95% CI)1.23–1.32 g/L (95% CI)1.33–1.39 g/L (95% CI)1.40–1.45 g/L (95% CI)1.46–1.52 g/L (95% CI)1.53–1.59 g/L (95% CI)1.60–1.66 g/L (95% CI)1.67–1.75 g/L (reference)1.76–1.91 g/L (95% CI)1.91–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.65 (1.56–1.75); P < 0.00011.32 (1.25–1.40); P < 0.00011.17 (1.10–1.24); P < 0.00011.08 (1.02–1.15); P = 0.00741.03 (0.97–1.10); P = 0.28871.07 (1.01–1.13); P = 0.03411.02 (0.96–1.08); P = 0.60251.001.03 (0.97–1.10); P = 0.30851.09 (1.03–1.15); P = 0.0053
Adjusteda1.31 (1.24–1.39); P < 0.00011.13 (1.06–1.20); P < 0.00011.03 (0.97–1.09); P = 0.35631.00 (0.94–1.06); P = 0.90070.97 (0.91–1.03); P = 0.26421.02 (0.96–1.08); P = 0.49890.99 (0.93–1.05); P = 0.75451.001.06 (1.00–1.13); P = 0.05331.14 (1.07–1.21); P < 0.0001
PGS Adjustedb1.29 (1.22–1.37); P < 0.00011.12 (1.05–1.18); P = 0.00041.02 (0.96–1.08); P = 0.54950.99 (0.93–1.05); P = 0.73160.96 (0.91–1.03); P = 0.23771.02 (0.96–1.08); P = 0.61020.99 (0.93–1.05); P = 0.69581.001.07 (1.01–1.14); P = 0.0321.15 (1.08–1.22); P < 0.0001
CV mortalityUnadjusted2.08 (1.87–2.31); P < 0.00011.52 (1.36–1.69); P < 0.00011.32 (1.18–1.47); P < 0.00011.24 (1.10–1.39) P = 0.00021.11 (0.99–1.25) P = 0.07881.22 (1.08–1.36); P = 0.00081.05 (0.94–1.18); P = 0.39751.001.11 (0.99–1.25); P = 0.08111.09 (0.96–1.23); P = 0.1757
Adjusteda1.35 (1.20–1.51); P < 0.00011.12 (1.00–1.26); P = 0.04561.03 (0.91–1.15); P = 0.66221.03 (0.92–1.16); P = 0.59460.95 (0.85–1.07); P = 0.41791.10 (0.98–1.23); P = 0.11430.99 (0.88–1.12); P = 0.86761.001.18 (1.04–1.33); P = 0.00761.21 (1.07–1.37); P = 0.0022
PGS Adjustedb1.30 (1.16–1.46); P < 0.00011.09 (0.97–1.23); P = 0.13961.00 (0.89–1.13); P = 0.96171.01 (0.90–1.14); P = 0.820.94 (0.83–1.06); P = 0.29621.08 (0.96–1.22); P = 0.18680.99 (0.88–1.11); P = 0.84071.001.19 (1.05–1.34); P = 0.00561.23 (1.09–1.39); P = 0.0011

Cox proportional hazards models were used for all-cause death; Fine and Gray’s sub-distribution hazard models were used for cardiovascular death, treating the non-cardiovascular deaths as competing risks.

Adjusted for age, sex, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR.

Adjusted for age, sex, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR, PGS and top 10 principal components.

Statistical significance defined at P < 0.05 (bold font).

Table 2A
Open in new tab

Association between ApoA1 levels and adverse outcomes. Overall cohort

OutcomeModel0.42–1.22 g/L (95% CI)1.23–1.32 g/L (95% CI)1.33–1.39 g/L (95% CI)1.40–1.45 g/L (95% CI)1.46–1.52 g/L (95% CI)1.53–1.59 g/L (95% CI)1.60–1.66 g/L (95% CI)1.67–1.75 g/L (reference)1.76–1.91 g/L (95% CI)1.91–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.65 (1.56–1.75); P < 0.00011.32 (1.25–1.40); P < 0.00011.17 (1.10–1.24); P < 0.00011.08 (1.02–1.15); P = 0.00741.03 (0.97–1.10); P = 0.28871.07 (1.01–1.13); P = 0.03411.02 (0.96–1.08); P = 0.60251.001.03 (0.97–1.10); P = 0.30851.09 (1.03–1.15); P = 0.0053
Adjusteda1.31 (1.24–1.39); P < 0.00011.13 (1.06–1.20); P < 0.00011.03 (0.97–1.09); P = 0.35631.00 (0.94–1.06); P = 0.90070.97 (0.91–1.03); P = 0.26421.02 (0.96–1.08); P = 0.49890.99 (0.93–1.05); P = 0.75451.001.06 (1.00–1.13); P = 0.05331.14 (1.07–1.21); P < 0.0001
PGS Adjustedb1.29 (1.22–1.37); P < 0.00011.12 (1.05–1.18); P = 0.00041.02 (0.96–1.08); P = 0.54950.99 (0.93–1.05); P = 0.73160.96 (0.91–1.03); P = 0.23771.02 (0.96–1.08); P = 0.61020.99 (0.93–1.05); P = 0.69581.001.07 (1.01–1.14); P = 0.0321.15 (1.08–1.22); P < 0.0001
CV mortalityUnadjusted2.08 (1.87–2.31); P < 0.00011.52 (1.36–1.69); P < 0.00011.32 (1.18–1.47); P < 0.00011.24 (1.10–1.39) P = 0.00021.11 (0.99–1.25) P = 0.07881.22 (1.08–1.36); P = 0.00081.05 (0.94–1.18); P = 0.39751.001.11 (0.99–1.25); P = 0.08111.09 (0.96–1.23); P = 0.1757
Adjusteda1.35 (1.20–1.51); P < 0.00011.12 (1.00–1.26); P = 0.04561.03 (0.91–1.15); P = 0.66221.03 (0.92–1.16); P = 0.59460.95 (0.85–1.07); P = 0.41791.10 (0.98–1.23); P = 0.11430.99 (0.88–1.12); P = 0.86761.001.18 (1.04–1.33); P = 0.00761.21 (1.07–1.37); P = 0.0022
PGS Adjustedb1.30 (1.16–1.46); P < 0.00011.09 (0.97–1.23); P = 0.13961.00 (0.89–1.13); P = 0.96171.01 (0.90–1.14); P = 0.820.94 (0.83–1.06); P = 0.29621.08 (0.96–1.22); P = 0.18680.99 (0.88–1.11); P = 0.84071.001.19 (1.05–1.34); P = 0.00561.23 (1.09–1.39); P = 0.0011
OutcomeModel0.42–1.22 g/L (95% CI)1.23–1.32 g/L (95% CI)1.33–1.39 g/L (95% CI)1.40–1.45 g/L (95% CI)1.46–1.52 g/L (95% CI)1.53–1.59 g/L (95% CI)1.60–1.66 g/L (95% CI)1.67–1.75 g/L (reference)1.76–1.91 g/L (95% CI)1.91–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.65 (1.56–1.75); P < 0.00011.32 (1.25–1.40); P < 0.00011.17 (1.10–1.24); P < 0.00011.08 (1.02–1.15); P = 0.00741.03 (0.97–1.10); P = 0.28871.07 (1.01–1.13); P = 0.03411.02 (0.96–1.08); P = 0.60251.001.03 (0.97–1.10); P = 0.30851.09 (1.03–1.15); P = 0.0053
Adjusteda1.31 (1.24–1.39); P < 0.00011.13 (1.06–1.20); P < 0.00011.03 (0.97–1.09); P = 0.35631.00 (0.94–1.06); P = 0.90070.97 (0.91–1.03); P = 0.26421.02 (0.96–1.08); P = 0.49890.99 (0.93–1.05); P = 0.75451.001.06 (1.00–1.13); P = 0.05331.14 (1.07–1.21); P < 0.0001
PGS Adjustedb1.29 (1.22–1.37); P < 0.00011.12 (1.05–1.18); P = 0.00041.02 (0.96–1.08); P = 0.54950.99 (0.93–1.05); P = 0.73160.96 (0.91–1.03); P = 0.23771.02 (0.96–1.08); P = 0.61020.99 (0.93–1.05); P = 0.69581.001.07 (1.01–1.14); P = 0.0321.15 (1.08–1.22); P < 0.0001
CV mortalityUnadjusted2.08 (1.87–2.31); P < 0.00011.52 (1.36–1.69); P < 0.00011.32 (1.18–1.47); P < 0.00011.24 (1.10–1.39) P = 0.00021.11 (0.99–1.25) P = 0.07881.22 (1.08–1.36); P = 0.00081.05 (0.94–1.18); P = 0.39751.001.11 (0.99–1.25); P = 0.08111.09 (0.96–1.23); P = 0.1757
Adjusteda1.35 (1.20–1.51); P < 0.00011.12 (1.00–1.26); P = 0.04561.03 (0.91–1.15); P = 0.66221.03 (0.92–1.16); P = 0.59460.95 (0.85–1.07); P = 0.41791.10 (0.98–1.23); P = 0.11430.99 (0.88–1.12); P = 0.86761.001.18 (1.04–1.33); P = 0.00761.21 (1.07–1.37); P = 0.0022
PGS Adjustedb1.30 (1.16–1.46); P < 0.00011.09 (0.97–1.23); P = 0.13961.00 (0.89–1.13); P = 0.96171.01 (0.90–1.14); P = 0.820.94 (0.83–1.06); P = 0.29621.08 (0.96–1.22); P = 0.18680.99 (0.88–1.11); P = 0.84071.001.19 (1.05–1.34); P = 0.00561.23 (1.09–1.39); P = 0.0011

Cox proportional hazards models were used for all-cause death; Fine and Gray’s sub-distribution hazard models were used for cardiovascular death, treating the non-cardiovascular deaths as competing risks.

Adjusted for age, sex, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR.

Adjusted for age, sex, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR, PGS and top 10 principal components.

Statistical significance defined at P < 0.05 (bold font).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close